Compare Monster Beverage Corp (MNST) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Novartis AG — how do they compare? Monster Beverage Corp trades at $94.46 (market cap $93.35B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.1× Monster Beverage Corp's market cap, and Novartis AG pays a 3.17% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | NVS | |
|---|---|---|
Market Cap | $93.35B | $290.25B |
Sector | Consumer Staples | Health |
52-Week High | $99.94 | $168.62 |
52-Week Low | $58.75 | $113.50 |
Enterprise Value | $91.65B | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $94.46, down 3.12% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.58 exceeding the $0.527 estimate, and maintains robust profitability with a net income margin of 23.11%. A 2-for-1 stock split is scheduled for August 2026, reflecting confidence in future growth.
The investment outlook is positive, driven by consistent earnings outperformance, international expansion, and product innovation. Risks include elevated valuation multiples (P/E of 46.11) and competitive pressures in the beverage sector. Analyst consensus is bullish with a $97.83 price target, suggesting modest upside from current levels.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
